Published in Clin Cancer Res on June 01, 2001
Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology (2014) 1.46
Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1. Nat Immunol (2013) 1.41
Shear stress and shear rate differentially affect the multi-step process of leukocyte-facilitated melanoma adhesion. Exp Cell Res (2005) 1.37
Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int (2007) 1.34
Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev (2011) 1.26
Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 1.26
Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol (2011) 1.26
Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel) (2010) 1.22
Molecular and functional analysis of an interferon gene from the zebrafish, Danio rerio. J Virol (2003) 1.19
Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene (2002) 1.18
Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci U S A (2003) 1.14
Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol (2011) 1.12
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res (2008) 1.11
Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer (2010) 1.08
socs7, a target gene of microRNA-145, regulates interferon-β induction through STAT3 nuclear translocation in bladder cancer cells. Cell Death Dis (2013) 1.05
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem (2003) 1.04
Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J Virol (2002) 1.02
Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine (2008) 0.95
Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma. Biochem J (2005) 0.95
Type I interferon induction is detrimental during infection with the Whipple's disease bacterium, Tropheryma whipplei. PLoS Pathog (2010) 0.94
Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotechnol (2011) 0.92
Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res (2006) 0.90
Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy (2013) 0.89
IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. PLoS One (2013) 0.89
Cytokine networks in glioma. Neurosurg Rev (2011) 0.88
Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas. J Immunother (2013) 0.87
Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res (2013) 0.87
Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res (2013) 0.84
The role of cell type-specific responses in IFN-β therapy of multiple sclerosis. Proc Natl Acad Sci U S A (2011) 0.84
Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol Cell Biol (2012) 0.84
Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma. PLoS One (2013) 0.83
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget (2014) 0.82
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res (2011) 0.82
Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells. Cell Death Dis (2013) 0.81
The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease. Clin Exp Immunol (2014) 0.81
Distinct Functions of Neutrophil in Cancer and Its Regulation. Mediators Inflamm (2015) 0.80
The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling. J Interferon Cytokine Res (2013) 0.80
Interferon-gamma enhances radiation-induced cell death via downregulation of Chk1. Cancer Biol Ther (2012) 0.80
Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev (2007) 0.80
Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity. Radiother Oncol (2008) 0.80
The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-α/β-mediated apoptosis in Ubp43-deficient hematopoietic cells. Biochem Biophys Res Commun (2012) 0.79
Helper T lymphocyte response in the peripheral blood of patients with intraepithelial neoplasia submitted to immunotherapy with pegylated interferon-α. Int J Mol Sci (2015) 0.79
The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response. PLoS One (2014) 0.78
TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis. J Urol (2010) 0.78
Differential growth and responsiveness to cancer therapy of tumor cells in different environments. Clin Exp Metastasis (2015) 0.77
Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-gamma and TNF-alpha. BMC Cancer (2010) 0.76
Lipopolysaccharide (LPS) Promotes Apoptosis in Human Breast Epithelial × Breast Cancer Hybrids, but Not in Parental Cells. PLoS One (2016) 0.76
STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat Struct Mol Biol (2017) 0.76
Sensitization of glycoengineered interferon-β1a-resistant cancer cells by cFLIP inhibition for enhanced anti-cancer therapy. Oncotarget (2017) 0.75
Differential Effects of IFN-β on the Survival and Growth of Human Vascular Smooth Muscle and Endothelial Cells. Biores Open Access (2015) 0.75
Alternative splicing of the OCC-1 gene generates three splice variants and a novel exonic microRNA, which regulate the Wnt signaling pathway. RNA (2016) 0.75
In vivo growth and responses to treatment of renal cell carcinoma in different environments. Am J Cancer Res (2017) 0.75
The TEL-AML1 fusion protein of acute lymphoblastic leukemia modulates IRF3 activity during early B-cell differentiation. Oncogene (2015) 0.75
Human umbilical cord matrix-derived stem cells expressing interferon-β gene inhibit breast cancer cells via apoptosis. Oncotarget (2016) 0.75
Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. Mol Ther (2017) 0.75
Mitochondrial pathways are involved in Eimeria tenella-induced apoptosis of chick embryo cecal epithelial cells. Parasitol Res (2016) 0.75
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38
The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest (1996) 1.14
Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13
Interferons as hormones of pregnancy. Endocr Rev (1992) 1.11
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08
Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res (1997) 1.06
Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J Immunol (1978) 1.05
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05
Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res (1992) 1.04
Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem (1999) 1.04
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene (2007) 1.03
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. Nat New Biol (1971) 1.03
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med (1992) 1.03
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem (1996) 1.02
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst (1989) 1.02
Mechanistic studies of polyene enhancement of interferon production by polyriboinosinic-polyribocytidylic acid. Antimicrob Agents Chemother (1978) 1.01
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res (1993) 0.99
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res (1990) 0.98
The effect of interferon on the metabolism of LDLs. Arterioscler Thromb (1992) 0.98
Studies on the poxvirus Cotia. J Gen Virol (1980) 0.97
Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha. J Interferon Res (1985) 0.97
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer (1978) 0.97
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene (2012) 0.96
Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol (1994) 0.96
Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res (1989) 0.94
Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res (1997) 0.93
2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals. AIDS (1991) 0.93
Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest (1985) 0.93
An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod (1985) 0.93
Participation of JAK and STAT proteins in growth hormone-induced signaling. J Biol Chem (1996) 0.92
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest New Drugs (1990) 0.92
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer (2011) 0.91
The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein. J Immunol (1975) 0.91
Interferons: biochemical, cell growth inhibitory, and immunological effects. Prog Hematol (1981) 0.91
Interferons: rationale for clinical trials in neoplastic disease. Ann Intern Med (1979) 0.90
Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol (1992) 0.90
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene (2011) 0.89
Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J Immunother Emphasis Tumor Immunol (1993) 0.89
2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol (2000) 0.89
Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer (1997) 0.88
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol (1987) 0.87
Effects of amphotericin B and its methyl ester on the antiviral activity of polyinosinic:polycytidylic acid. Antimicrob Agents Chemother (1979) 0.87
Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines. J Urol (1991) 0.87
Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol Cell Biochem (1997) 0.87
Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther (1997) 0.87
Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res (1989) 0.87
Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells. J Immunol (1984) 0.86
Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol (1983) 0.86
Comparison of agar and agarose preparations for mengovirus plaque formation. Appl Microbiol (1970) 0.86
Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. Cancer Res (1984) 0.86
Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J Interferon Res (1993) 0.85
Interferon action against human parainfluenza virus type 3: involvement of a novel antiviral pathway in the inhibition of transcription. J Virol (2001) 0.85
Hypertrophic osteoarthropathy and pregnancy. Ann Intern Med (1969) 0.85
Progress toward therapeutic application of interferons, 1979-1983. Cancer (1984) 0.85
Tacaribe virus infection of the mouse: an immunopathologic disease model. Lab Invest (1974) 0.84
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration. J Interferon Res (1986) 0.84
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol (1992) 0.84
Recombinant interferon-gamma preserves human granulocyte bactericidal and chemoluminescence activities. J Infect Dis (1993) 0.83
John Locke, physician and author of the first Carolina Constitution. South Med J (1967) 0.83
Absence of biological effects of orally administered interferon-beta ser. J Interferon Res (1992) 0.83
Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst (1989) 0.83
Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis (1987) 0.83
Role of interferons in maternal recognition of pregnancy in ruminants. Proc Soc Exp Biol Med (1992) 0.82
Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol (1984) 0.82
Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Cancer Biother Radiopharm (1998) 0.81
Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains. J Biol Chem (1987) 0.81
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. Clin Pharmacol Ther (2007) 0.81
Interferons and cancer: how the promise is being kept. Interferon (1983) 0.81
Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. Cancer Treat Rep (1983) 0.81
Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. Cancer Res (1990) 0.81
Enhancement of infectivity of encephalomyocarditis virus RNA by amphotericin B methyl ester. J Gen Virol (1979) 0.80